...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study
【24h】

Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study

机译：常规化疗联合碘-125种子植入肝细胞癌患者：回顾性控制研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To determine if iodine-125 seed implantation improved the efficacy of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) (≤5?cm). Methods We retrospectively reviewed the medical records of 83 consecutive patients with HCC (≤5?cm) who underwent TACE or TACE–iodine-125 from January 2014 to July 2017. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS) and objective response rate (ORR) at 3 months after the first TACE treatment. PFS and OS were calculated using the Kaplan–Meier method and compared using log-rank tests. Independent risk factors for PFS and OS were analyzed using a Cox proportional hazards model. Results Thirty-five patients received TACE–iodine-125 and 48 received TACE alone. The median OS and PFS were both significantly longer in the TACE–iodine-125 compared with the TACE-alone group (42 vs 23 months and 16 vs 8 months, respectively). The ORR was significantly higher in the TACE–iodine-125 compared with the TACE-alone group. There was no significant difference in adverse events, apart from decreased white cell count, between the two groups. Conclusion TACE–iodine-125 might be an effective and safe alternative treatment for patients with HCC (≤5?cm).
机译：目的确定碘-125种子植入是否改善了肝细胞癌（HCC）患者（≤5Ωcm）的常规化疗栓塞（TACE）的疗效。方法回顾性地审查了83例连续83例HCC（≤5厘米）的医疗记录，他于2014年1月至2017年7月接受了TACE或TACE-IODINE-125.主要终点是无进展的生存（PFS）。次要终点在第一次TACE治疗后3个月内总存活（OS）和客观反应率（ORR）。使用Kaplan-Meier方法计算PFS和OS，并使用日志排名测试进行比较。使用COX比例危险模型分析了PFS和OS的独立风险因素。结果35名患者接受TACE-IODINE-125和48仅接受TACE。与TACE-INS-INODINE-125相比，中位OS​​和PFS在TACE-IODINE-125中均明显更长（42 vs 23个月和16个月8个月）。与单独的TACE-INODINE-125，TACE-IODINE-125的ORR显着高。除了两组之间，除了白细胞计数下降之外，不良事件没有显着差异。结论TACE-IODINE-125可能是HCC（≤5≤CM）的有效和安全的替代治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号